Chin Pregabalin Market Report, 2018-2022 Featuring Chongqing Succeway Pharmaceutical & Pfizer

News provided by

Jul 24, 2018, 13:15 ET

DUBLIN, July 24, 2018 /PRNewswire/ --

The "Investigation Report on Chinese Pregabalin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Pregabalin is a new-generation drug for neuralgia treatment. In Jul. 2004, it was approved by the European Union to treat some epileptic seizures in adults. In Dec. 2004, it was approved by the U.S. Food and Drug Administration (FDA) to treat diabetic peripheral neuralgia and postherpetic neuralgia. In 2006, generalized anxiety disorder and social anxiety disorder became new indications of Pregabalin. In 2007, Pregabalin was approved by the FDA as the first drug to treat fibromyalgia syndrome. In 2012, Pregabalin was approved by the FDA to treat spinal cord injury (SCI)-related pains. In 2010, Lyrica was approved to enter China.

According to the research, the sales value of Lyrica increased by more than 200 times from about CNY 200,000 in 2010 to over 40 million in 2017. Due to Lyrica's success, many domestic manufacturers applied for Pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd.'s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer.

By sales value, in 2017, Pfizer's Lyrica had a market share of approximately 79.8%, and the rest market share was captured by the products of Chongqing Succeway Pharmaceutical Co., Ltd. It is estimated that Pfizer's Lyrica will continue to dominate the Chinese market from 2018 to 2022 but its market share will decline because of the price competition of China-made Pregabalin.

There is a continuous rise in the number of people suffering from indications for Pregabalin. For example, the number of epileptics in China has exceeded 10 million and increases by 400,000 every year. Therefore, Pregabalin has a bright prospect in China.

Key Topics Covered:

1 Relevant Concepts of Pregabalin
1.1 Indications for Pregabalin
1.2 Development History of Pregabalin in China
1.3 Governmental Approval of Pregabalin in China

2 Sales of Pregabalin in China, 2013-2017
2.1 Sales Value of Pregabalin in China
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Pregabalin in China
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Analysis on Dosage Forms of Pregabalin

3 Major Pregabalin Manufacturers in China, 2013-2017
3.1 Analysis on Major Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Pfizer
3.2.1 Enterprise Profile
3.2.2 Sales of Pfizer's Pregabalin in China
3.3 Chongqing Succeway Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Chongqing Succeway Pharmaceutical Co., Ltd.'s Pregabalin in China

4 Prices of Pregabalin in China, 2017-2018
4.1 Averages Prices of Pregabalin in China
4.1.1 National Average Price
4.1.2 Average Price by Region
4.2 Prices of Major Manufacturers' Pregabalin in China
4.2.1 Pfizer (Lyrica)
4.2.2 Chongqing Succeway Pharmaceutical Co., Ltd. (Lairuike)

5 Prospects of Chinese Pregabalin Market, 2018-2022
5.1 Factors Influencing Pregabalin Development in China
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Generic Drugs
5.3 Forecast on Market Size of Pregabalin in China, 2018-2022
5.4 Forecast on Competition Pattern of Pregabalin in China

For more information about this report visit https://www.researchandmarkets.com/research/qd7p5w/chin_pregabalin?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets